Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
- Conditions
- Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide, 15%Drug: Vehicle
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 351
- Registration Number
- NCT03948646
- Locations
- πΊπΈ
Cahaba Dermatology Skin & Health Center, Birmingham, Alabama, United States
πΊπΈAdvanced Research Associates, Glendale, Arizona, United States
πΊπΈArkansas Research Trials, North Little Rock, Arkansas, United States
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
- Conditions
- Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide Gel, 15%Drug: Vehicle
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT03836287
- Locations
- πΊπΈ
Total Skin and Beauty Dermatology Center, P.C., Birmingham, Alabama, United States
πΊπΈInvestigate MD, LLC, Scottsdale, Arizona, United States
πΊπΈNorthwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT03824405
- Locations
- πΊπΈ
Applied Research Center of Arkansas Inc., Little Rock, Arkansas, United States
πΊπΈT. Joseph Raoff MD Inc. / Encino Research Center, Encino, California, United States
πΊπΈCenter for Dermatology Clinical Research, Fremont, California, United States
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
- Conditions
- Primary Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide Gel, 15%
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT03785587
- Locations
- πΊπΈ
Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
- Conditions
- Primary Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide Gel, 5%Drug: Sofpironium Bromide Gel, 15%
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT03627468
- Locations
- πΊπΈ
Coastal Clinical Research, Inc., Mobile, Alabama, United States
πΊπΈNorthwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
πΊπΈCenter for Clinical and Cosmetic Research, Aventura, Florida, United States
- Prev
- 1
- 2
- 3
- Next